AmCad BioMed Corporation (4188.TWO)
TWD 21.35
(-0.23%)
TWD 21.35
(-0.23%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -41.59 Million | -34.19 Million | -38.96 Million | -50.04 Million | - |
| Net Income | -43.14 Million | -54.34 Million | -26.89 Million | -43.02 Million | - |
| Depreciation & Amortization | 17.46 Million | 17.62 Million | 18.28 Million | 19.66 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 676 Thousand | 821 Thousand | 540 Thousand | -176 Thousand | - |
| Change in working capital | -16.75 Million | 1.75 Million | -30.87 Million | -27.19 Million | - |
| Other non-cash items | -4.18 Million | -3.02 Million | -2.46 Million | -3 Million | - |
| Investing Cash Flow | 27.31 Million | 27.14 Million | 49.18 Million | 5.91 Million | - |
| Investments in PPE | -293 Thousand | -614 Thousand | -2.33 Million | -320 Thousand | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | 23.17 Million | 25.76 Million | 7.43 Million | -29.57 Million | - |
| Sales/Maturities of investments | 3.01 Million | 3 Million | 43.75 Million | 37.71 Million | - |
| Other Investing Activities | 1.41 Million | -1 Million | 333 Thousand | -1.89 Million | - |
| Financing Cash Flow | -3.09 Million | -4.41 Million | -11.34 Million | -5.01 Million | - |
| Debt repayment | -4.41 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 1.32 Million | - | - | - | 2.31 Million |
| Other Financing Activities | -4.41 Million | 8000.00 | -6.8 Million | - | 280 Thousand |
| Accounts receivables | -6.79 Million | - | - | - | - |
| Accounts payables | 962 Thousand | - | - | - | - |
| Inventory | -5.41 Million | -2.6 Million | 17 Thousand | -2.42 Million | - |
| Other working capital | -4.55 Million | - | - | - | - |
| Cash at beginning of period | 47.04 Million | 58.51 Million | 59.64 Million | 108.79 Million | - |
| Cash at end of period | 29.65 Million | 47.04 Million | 58.51 Million | 59.64 Million | - |
| Capital Expenditure | -293 Thousand | -614 Thousand | -2.33 Million | -320 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -17.38 Million | -11.46 Million | -1.13 Million | -49.14 Million | - |
| Free Cash Flow | -41.89 Million | -34.8 Million | -41.3 Million | -50.36 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -11.16 Million | -18.37 Million | -7.15 Million | -43.14 Million | -11.7 Million | -12.05 Million |
| Depreciation & Amortization | 4.68 Million | 4.68 Million | 4.37 Million | 17.46 Million | 4.36 Million | 4.35 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 185 Thousand | 185 Thousand | 247 Thousand | 676 Thousand | 175 Thousand | 147 Thousand |
| Change in working capital | -6.41 Million | -1.84 Million | -4.52 Million | -16.75 Million | -3.61 Million | -1.79 Million |
| Other non-cash items | -988 Thousand | -985 Thousand | -1.09 Million | -4.18 Million | -958 Thousand | -1.11 Million |
| Investing Cash Flow | 12.57 Million | 12.96 Million | 12.74 Million | 27.31 Million | 12.4 Million | 287 Thousand |
| Investments in PPE | -90 Thousand | - | -104 Thousand | -293 Thousand | -85 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -23.89 Million | -38 Million | 13.06 Million | 23.17 Million | 12.49 Million | -1.38 Million |
| Sales/Maturities of investments | 36.88 Million | 50.48 Million | - | 3.01 Million | - | - |
| Other Investing Activities | 12.66 Million | 479 Thousand | -213 Thousand | 1.41 Million | - | 1.66 Million |
| Financing Cash Flow | -1.31 Million | -915 Thousand | -348 Thousand | -3.09 Million | -523 Thousand | -1.11 Million |
| Debt repayment | -1.31 Million | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 391 Thousand | 743 Thousand | 1.32 Million | 577 Thousand | - |
| Other Financing Activities | -1.31 Million | - | - | - | - | - |
| Accounts receivables | -5.78 Million | - | - | - | - | - |
| Accounts payables | 1.16 Million | - | - | - | - | - |
| Inventory | -2.83 Million | -2.15 Million | -1.04 Million | -5.41 Million | -2.1 Million | -1.76 Million |
| Other working capital | 2.41 Million | - | - | - | - | - |
| Cash at beginning of period | 26.34 Million | 29.65 Million | 24.31 Million | 47.04 Million | 23.05 Million | 33.22 Million |
| Cash at end of period | 24.96 Million | 26.34 Million | 29.65 Million | 29.65 Million | 24.31 Million | 23.05 Million |
| Capital Expenditure | -90 Thousand | - | -104 Thousand | -293 Thousand | -85 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -1.38 Million | -3.31 Million | 5.34 Million | -17.38 Million | 1.26 Million | -10.17 Million |
| Free Cash Flow | -12.74 Million | -15.35 Million | -7.15 Million | -41.89 Million | -10.7 Million | -9.34 Million |
JSL
0HWH
2291
TLL
GEM
9869